

National Federation of Nurses' Unions—Cont.

Political affiliations, views, Canadian Nurses' Association ties, etc., 9:34-5

See also Committee; Witnesses

National Health and Welfare Department

Health Protection Branch see Drugs and pharmaceuticals; Drugs and pharmaceuticals industry, Employment

Minister, Bill C-22 cost impact studies, information requesting, 11:61

M. (Dingwall), 13:32-5, negated on recorded division, 3

National Pensioners and Senior Citizens Federation

Legislation, Bill C-22 opposing, 12:23

See also Witnesses

National Research Council

Government cut-backs, 3:36; 11:7, 17; 15:48

National Revenue Department see Drugs and pharmaceuticals industry—Transfer pricing issue; Research and development—Defining**New Democratic Party**

Fundraising campaign against Bill C-22, 3:38-9; 4:14, 23; 10:28

See also Biotechnology industry; Carr—References

New York State see Drug plans**Nickerson, Prof.**

References, 13:28

Nobel laureates, 3:58**NOC see Notice of compliance****Non-ionic contrast media see Health care—Hospitals****Nordic Laboratories Inc., 1:34; 17:33, 50**

Background, 11:13-4, 16

Norman, Doris (Kidney Foundation of Canada)

Patent Act (amdt.)(Bill C-22), 13:3, 5-9, 12-4

North Carolina see High technology centres**Notice of compliance see Brand name drugs—Exclusivity period from imports; Generic drugs—Compulsory licensing****Nova Scotia see Drugs and pharmaceuticals—Provinces****Nurses**

Unionized, Bill C-22 position, 9:26-7

See also Health care—Drugs

Ojibway Nation

Diseases, health problems, 9:41

Ontario

Health Minister Elston letter to Andre re Bill C-22, tabling, 17:19-21

See also Drug plans; Drugs and pharmaceuticals—Provinces;

Health care; Prescription Drug Cost Regulation Act; University Research Incentive Fund

Ontario Advisory Council on Senior Citizens

Report, 12:24

Ontario Drug Benefit Plan

Costs, Bill C-22 increasing, 6:79-80

Product selection, mandatory, 6:75-6

Ontario Hospital Association see Generic drugs—Compulsory licensing**Ontario Medical Reform Group**

Background, 9:48; 13:31

Generic drug resolution, 9:42, 49

See also Witnesses

Orders of Reference, 1:3**Organization for Economic Co-operation and Development see Drugs and pharmaceuticals industry—World class****Organization meeting see Procedure and Committee business****Organizations appearing see Witnesses****Orlikow, David (NDP—Winnipeg North)**

American Association of Retired Persons, 12:23

Ayerst Laboratories; 15:39

Bio-medical research, 10:40-1

Biotechnology industry, 8:42, 56; 12:47-8

Brand name drugs, 1:23-5, 3:17, 58; 5:17-9; 6:41-2, 56; 7:10; 8:55;

9:32-3, 47; 10:7-8, 26; 11:12, 26-8; 12:10-2, 36-8, 48-50, 59;

13:28, 43; 14:14-5, 42-3, 50-1, 60-1, 71; 15:13-4, 25-6, 37-8,

48-9, 60; 16:17, 23, 25, 71, 86-7; 17:23

Canadian Cancer Society, 16:20-3, 25

Canadian Chamber of Commerce, 8:22

Canadian Council on Social Development, 6:66

Canadian Federation of Biological Societies, 12:38

Canadian Hospital Association, 9:32

Cangene Corp., 16:17, 58, 62

Committee, 9:40

Consumer and Corporate Affairs Department, M. (Dingwall), 13:33-5

Consumers, 6:15, 17, 24

Cystic fibrosis, 9:14-5

Dalhousie University Medical School, 12:36-7; 15:13, 38

Disabled and handicapped, 15:79

Diseases, 15:11

Drug patents, 8:23; 11:12-3; 12:58; 14:42; 16:17, 35-7, 43-4, 48, 53-5, 58

Drug plans, 8:12, 22; 9:46-7; 11:26; 12:24, 26, 58, 70; 14:14, 27-8; 15:61-2

Drug prescriptions, 15:80

Drug Prices Review Board, 3:15; 5:19, 28-9; 6:16-7, 54-5, 68; 7:12-3;

8:63; 11:27; 12:49, 70-1; 13:9-10; 14:15, 29, 41, 71-2; 15:25, 38,

48-9, 81; 16:70, 74-5

Drugs and pharmaceuticals, 1:25, 43-4; 3:16; 5:17-9; 6:15; 6:55, 67;

8:11, 43, 55-6; 10:9; 12:11, 24, 57-9, 69; 13:8-9, 26; 14:13-4, 27,

41-2, 61-2, 69-70, 72; 15:24-5, 37, 60, 62, 80, 94-5; 1:16

Drugs and pharmaceuticals industry, 1:22; 3:15, 55-7; 6:25-6;

7:11-2; 11:11-2; 12:12-3, 36, 71; 13:27, 43-4; 14:61; 15:37, 47-8

Federal Superannuates Association, 14:59-60

Free enterprise system, 3:40-1

Free trade, Canada-United States negotiations, 10:27

Generic drugs, 3:39-40; 6:54; 8:24, 64; 9:16; 10:9, 27; 12:11, 69-70; 13:25

Gorecki, references, 14:69

Green Shield Prepaid Services Inc., 14:26-7

Health care, 9:31-2, 33, 48; 12:24-5; 15:23-4, 95

Keystone Agriculture Producers, 8:44; 16:16

Medical Research Council, 7:11; 11:11; 12:58; 13:25-6, 44; 14:13, 49-51; 15:12-3

Multiple sclerosis, 8:11-2

Multiple Sclerosis Society of Ottawa-Carleton, 8:10-1, 24

National Health and Welfare Department, M. (Dingwall), 13:33-5

National Research Council, 15:48

Nickerson, references, 13:28

Nordic Laboratories Inc., 17:50

Ontario, 17:21